Division of Nephrology and Hypertension Archive — Page 8 of 9
-
January 8, 2015
Integrin discovery may lead to better lung treatments
Vanderbilt University researchers have made an important advance in understanding lung development, which one day could lead to improvements in treating lung disease in premature infants and adults. -
October 30, 2014
NIH grant spurs diabetic nephropathy research
Diabetic nephropathy, or kidney disease caused by diabetes, is a major source of morbidity and mortality. In the United States, more than 30 percent of patients receiving either dialytic therapy or renal transplantation have end stage renal disease as a result of diabetic nephropathy. -
July 31, 2014
Photo: Summer research conference
Undergraduates from across the country attended a summer research conference at Vanderbilt this week sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. -
July 10, 2014
Molecular ‘chat’ holds kidney fibrosis clues
A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process. -
June 26, 2014
VU study shows common diabetes drug can slow chronic kidney disease progression
Vanderbilt investigators have demonstrated in two studies that metformin-based treatments delay the onset and progression of chronic kidney disease (CKD) compared with other treatments for diabetes. -
May 29, 2014
New center dedicated to kidney disease
Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer. -
May 8, 2014
Nighttime dialysis treatments available
Vanderbilt University Medical Center, committed to providing multiple options to patients who have kidney disease, recently began offering nocturnal in-center hemodialysis, which allows patients to receive treatment at night while they sleep.